Literature DB >> 29609755

Bempedoic Acid (ETC-1002): A Current Review.

Anum Saeed1, Christie M Ballantyne2.   

Abstract

Although statins are first-line therapy for low-density lipoprotein cholesterol (LDL-C) reduction, many individuals on maximally tolerated statin therapy have elevated LDL-C. Bempedoic acid (ETC-1002) is a novel once-daily LDL-C-lowering agent in phase 3 clinical trials. In phase 1 and 2 studies, ETC-1002 was efficacious in lowering LDL-C when used as monotherapy and when added to statin and/or ezetimibe and was well tolerated in patients with statin intolerance. ETC-1002 also improved cardiometabolic risk factors. Ongoing phase 3 studies of ETC-1002 are evaluating its long-term efficacy and safety, and effects on cardiovascular events. This article discusses current evidence and future directions for ETC-1002.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bempedoic acid; Cardiovascular disease; Cholesterol; Lipid-lowering agents; Lipids; Nonstatin therapy; Statin intolerance

Mesh：

Substances：

Year:  2018        PMID： 29609755     DOI： 10.1016/j.ccl.2017.12.007

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN： 0733-8651            Impact factor:   2.213


  8 in total

Review 1.  Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.

Authors:  Xiaoming Jia; Jing Liu; Anurag Mehta; Christie M Ballantyne; Salim S Virani
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-30       Impact factor: 3.727

Review 2.  Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.

Authors:  Andrey V Susekov; Ludmila A Korol; Gerald F Watts
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-27       Impact factor: 3.727

3.  Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.

Authors:  Xiang Zhao; Xubiao Ma; Xing Luo; Zhihua Shi; Ziwen Deng; Yuanxiang Jin; Zhipeng Xiao; Liming Tan; Pingfang Liu; Shilong Jiang; Yuanglu Shu; Bing Tang; Chengfeng Qiu
Journal:  BMC Pharmacol Toxicol       Date:  2020-12-04       Impact factor: 2.483

4.  Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.

Authors:  Brian Tomlinson; Nivritti Gajanan Patil; Manson Fok; Christopher Wai Kei Lam
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

Review 5.  Management of Familial Hypercholesterolemia: Current Status and Future Perspectives.

Authors:  David T W Lui; Alan C H Lee; Kathryn C B Tan
Journal:  J Endocr Soc       Date:  2020-08-21

Review 6.  Novel therapeutic targets and agents for pediatric dyslipidemia.

Authors:  Bhuvana Sunil; Christy Foster; Don P Wilson; Ambika P Ashraf
Journal:  Ther Adv Endocrinol Metab       Date:  2021-11-24       Impact factor: 3.565

Review 7.  Low-density lipoprotein cholesterol lowering treatment: the current approach.

Authors:  Irina Crismaru; Anca Pantea Stoian; Ovidiu Gabriel Bratu; Mihnea-Alexandru Gaman; Ana Maria Alexandra Stanescu; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Lipids Health Dis       Date:  2020-05-06       Impact factor: 3.876

8.  Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.

Authors:  Xing Wang; Yu Zhang; Huiwen Tan; Peng Wang; Xi Zha; Weelic Chong; Liangxue Zhou; Fang Fang
Journal:  Cardiovasc Diabetol       Date:  2020-08-12       Impact factor: 9.951
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.